{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:20:21Z","timestamp":1787026821585,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T00:00:00Z","timestamp":1630281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>\n                    <jats:bold>Purpose:<\/jats:bold>\n                    To evaluate the efficacy and tolerability of adjunctive perampanel (PER) in Chinese patients with focal-onset seizures, with or without secondarily generalized tonic-clonic seizures.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Fifty-six patients aged 14\u201372 years were recruited consecutively in this single-center prospective observational study. All patients received PER as add-on treatment on the basis of clinical judgment. Seizure frequency, adverse events (AEs), and retention rates were obtained at 3 and 6 months after PER introduction.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    The overall response rates were 60 and 71.1% after 3 and 6 months, respectively, and the freedom of seizures at the same points were reached in 8 and 15.8%. The retention rates were 89.3% at the 3-month follow-up and 67.9% at the 6-month follow-up. The overall incidence of adverse events was 55.4%. The leading reported AEs were dizziness (39.3%) and somnolence (25%).\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Our study confirmed the efficacy and tolerability of adjunctive PER in Chinese patients in real-life conditions. Based on our treatment experience, a lower maintenance dose of PER would be needed in Chinese patients.\n                  <\/jats:p>","DOI":"10.3389\/fneur.2021.731566","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:39:56Z","timestamp":1630931996000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Efficacy and Tolerability of Perampanel as Adjunctive Therapy in Chinese Patients With Focal-Onset Seizures: An Observational, Prospective Study"],"prefix":"10.3389","volume":"12","author":[{"given":"Ranran","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiqin","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianwen","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,8,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000493484","article-title":"Aging and the epidemiology of epilepsy","volume":"51","author":"Beghi","year":"2018","journal-title":"Neuroepidemiology"},{"key":"B2","doi-asserted-by":"publisher","first-page":"964","DOI":"10.2471\/blt.07.047050","article-title":"Global campaign against epilepsy: assessment of a demonstration project in rural China","volume":"86","author":"Wang","year":"2008","journal-title":"Bull World Health Organ"},{"key":"B3","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.2147\/NDT.S84852","article-title":"Managing drug-resistant epilepsy: challenges and solutions","volume":"12","author":"Dalic","year":"2016","journal-title":"Neuropsychiatr Dis Treat"},{"key":"B4","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1586\/ern.13.46","article-title":"AMPA receptor inhibitors for the treatment of epilepsy: the role of perampanel","volume":"13","author":"Zaccara","year":"2013","journal-title":"Expert Rev Neurother"},{"key":"B5","doi-asserted-by":"publisher","first-page":"464","DOI":"10.3390\/biom10030464","article-title":"Ionotropic glutamate receptors in epilepsy: a review focusing on AMPA and NMDA receptors","volume":"10","author":"Hanada","year":"2020","journal-title":"Biomolecules"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/17460441.2019.1566318","article-title":"The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery","volume":"14","author":"Lattanzi","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"B7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.eplepsyres.2015.04.011","article-title":"Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel","volume":"114","author":"Montouris","year":"2015","journal-title":"Epilepsy Res"},{"key":"B8","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/ane.12883","article-title":"Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study","volume":"137","author":"Nishida","year":"2018","journal-title":"Acta Neurol Scand"},{"key":"B9","doi-asserted-by":"publisher","first-page":"116903","DOI":"10.1016\/j.jns.2020.116903","article-title":"The efficacy of perampanel as adjunctive therapy in drug-resistant focal epilepsy in a \u201creal world\u201d context: focus on temporal lobe epilepsy","volume":"15","author":"Pascarella","year":"2020","journal-title":"J Neurol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"108069","DOI":"10.1016\/j.yebeh.2021.108069","article-title":"Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up","volume":"121","author":"Fernandes","year":"2021","journal-title":"Epilepsy Behav."},{"key":"B11","doi-asserted-by":"publisher","first-page":"106879","DOI":"10.1016\/j.yebeh.2019.106879","article-title":"Perampanel tolerability in children and adolescents with focal epilepsy: effects on behavior and executive functions","volume":"103","author":"Operto","year":"2020","journal-title":"Epilepsy Behav"},{"key":"B12","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.braindev.2020.11.005","article-title":"Clinical experience on the use of perampanel in epilepsy among child neurologists in the Philippines","volume":"43","author":"Macrohon","year":"2021","journal-title":"Brain Dev"},{"key":"B13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3988\/jcn.2020.16.1.53","article-title":"Real-life effectiveness and tolerability of perampanel in pediatric patients aged 4 years or older with epilepsy: a Korean National Multicenter Study","volume":"16","author":"Hwang","year":"2020","journal-title":"J Clin Neurol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1111\/epi.16548","article-title":"Effectiveness and safety of perampanel monotherapy for focal and generalized tonic-clonic seizures: experience from a national multicenter registry","volume":"61","author":"Toledano Delgado","year":"2020","journal-title":"Epilepsia"},{"key":"B15","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"B16","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1111\/epi.14520","article-title":"Perampanel in routine clinical use across Europe: pooled, multicenter, observational data","volume":"59","author":"Rohracher","year":"2018","journal-title":"Epilepsia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/1756285616661115","article-title":"Two-year real-world experience with perampanel in patients with refractory focal epilepsy: Austrian data","volume":"9","author":"Rohracher","year":"2016","journal-title":"Ther Adv Neurol Disord"},{"key":"B19","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.eplepsyres.2016.08.001","article-title":"Safety, efficacy and outcome-related factors of perampanel over 12 months in a real-world setting: the FYDATA study","volume":"126","author":"Villanueva","year":"2016","journal-title":"Epilepsy Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/cns.13458","article-title":"Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies","volume":"27","author":"Weiping","year":"2021","journal-title":"CNS Neurosci Ther"},{"key":"B21","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1111\/epi.14044","article-title":"Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: study 307","volume":"59","author":"Krauss","year":"2018","journal-title":"Epilepsia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1111\/j.1528\u20131167.2011.03109.x","article-title":"Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy","volume":"52","author":"Hanada","year":"2011","journal-title":"Epilepsia"},{"key":"B23","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.seizure.2013.02.002","article-title":"Early predictors of outcome in newly diagnosed epilepsy","volume":"22","author":"Mohanraj","year":"2013","journal-title":"Seizure"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1212\/WNL.0000000000001558","article-title":"Perampanel efficacy and tolerability with enzyme-inducing ASMs in patients with epilepsy","volume":"84","author":"Gidal","year":"2015","journal-title":"Neurology"},{"key":"B25","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.seizure.2020.09.026","article-title":"Efficacy and tolerability of perampanel as a first add-on therapy with different anti-seizure drugs","volume":"83","author":"Santamarina","year":"2020","journal-title":"Seizure"},{"key":"B26","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/WNF.0000000000000255","article-title":"One-year retention study of adjunctive perampanel treatment in epilepsy patients","volume":"41","author":"Kim","year":"2018","journal-title":"Clin Neuropharmacol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"106876","DOI":"10.1016\/j.yebeh.2019.106876","article-title":"Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies","volume":"104","author":"Pi\u00f1a-Garza","year":"2020","journal-title":"Epilepsy Behav"},{"key":"B28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jns.2018.04.017","article-title":"Perampanel as adjunctive therapy in highly refractory epilepsies: real-world data from an Italian tertiary care epilepsy centre","volume":"390","author":"Morano","year":"2018","journal-title":"J Neurol Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/epi.16428","article-title":"Efficacy and safety of adjunctive perampanel 4 mg\/d for the treatment of focal seizures: a pooled post hoc analysis of four randomized, double-blind, phase III studies","volume":"61","author":"Steinhoff","year":"2020","journal-title":"Epilepsia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"116416","DOI":"10.1016\/j.jns.2019.08.001","article-title":"Efficacy and tolerability of perampanel as an adjunct therapy in refractory epilepsy from real-world experience","volume":"405","author":"Chang","year":"2019","journal-title":"J Neurol Sci"},{"key":"B31","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/ane.12529","article-title":"Perampanel for focal epilepsy: insights from early clinical experience","volume":"133","author":"Trinka","year":"2016","journal-title":"Acta Neurol Scand"},{"key":"B32","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.eplepsyres.2014.03.015","article-title":"A multicenter survey of clinical experiences with perampanel in real life in Germany and Austria","volume":"108","author":"Steinhoff","year":"2014","journal-title":"Epilepsy Res"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.731566\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T12:39:58Z","timestamp":1630931998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.731566\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,30]]},"references-count":32,"alternative-id":["10.3389\/fneur.2021.731566"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.731566","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,30]]},"article-number":"731566"}}